Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Pediatric Hematology/Oncology and ImmunopathologyOpen Access

Experience in developing and scaling a protocol for NK lymphocyte enriched cellular product manufacturing for clinical application

View Full Paper
Ask AI
Bookmark
Share

Authors

EKE. A. KulakovskayaVBV. E. BelchikovVVVictoria A. Vedmedskaia

Discussion

Loading...

Member takes

Overview

Protocol demonstrates effective NK cell expansion and cytotoxic activity in pediatric leukemia treatment.

Key Points

  • NK lymphocyte expansion protocol achieved desired clinical dosage, demonstrating effective cytotoxic activity.
  • Quality control criteria were met, with high percentage of NK cells and low percentage of residual TCRab+ T cells.
  • Independent Ethics Committee approved the process, confirming safety for pediatric leukemia treatment.
  • The protocol results establish a foundation for clinical study on NK lymphocyte-enriched products.

Cite This Study

Kulakovskaya et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478bb84https://doi.org/10.24287/1726-1708-2025-24-2-27-37
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel feeder cell based on 4-1BBL and membrane-bound IL-21/IL-15 induce highly expansion and anti-tumor effect of natural killer cells2025
  2. 2Preclinical feasibility analysis for Phase I study using adoptive iNKT cell transfer to prevent GVHD2025
  3. 3More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy2025
  4. 4Phenotyping of ex vivo expanded NK cells reveals unique transcriptomic and epigenetic signatures2025
  5. 5Scalable Process Development of NK and CAR-NK Expansion in a Closed Bioreactor Using 721.221-mIL21 Expansion System 24402025